威斯克

成都威斯克生物医药
成都威斯克生物医药

westvacbiopharmaisfoundedbyacademicianweiyuquanfromwestchinahospitalofsichuanuniversity,togetherwithscientistsfromstatekeylaboratoryofbiotherapy(sklb).itsheadquarterislocatedintheinternationalbio-town,chengdu.theceoofwestvacbiopharmaisprof.weiyuquan,whoistheacademicianofchineseacademyofsciencesaswellasthedirectorofstatekeylaboratoryofbiotherapy.westvaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.ithasattachedgreatimportanceintheresearchanddevelopment(r&d)ofcovid-vaccineespeciallyandbuildingacovid-vaccineproductionplatform.statekeylaboratoryofbiotherapy(sklb)wasestablishedbytheministryofsciencesandtechnologyofchinainandbecameoneofthenationalr&dplatformsfornoveldrugsfoundedbytheministriesofsciencesandtechnologyaswellasthatofhealthofchinain.itisalsosupportedbynationalcollaborativeinnovationprogramandhasbecomethenationalcollaborativeinnovationcenterforbiotherapysince.westchinahospitalofsichuanuniversity,foundedin,isthenationalcenterfordiagnosisandtreatmentofsevereandcriticaldiseasesinwesternchina.itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.relyingonthemedicalresourcesofstatekeylaboratoryofbiotherapyandwestchinamedicalcenter,westvachasadoptedrecombinantproteinmethodologytodevelopthecovid-vaccine.becauseofthesafetyoftheproteinvaccine,itisalsotheonlycovid-vaccineapprovedfortheuseinchildrenoveryearsoldinchina.thevaccinewasapprovedbythenationalmedicalproductsadministrationforclinicaltrialsonaugust,.phasei/iiclinicaltrialshavebeencompleted,andphaseiiiclinicaltrialsarebeingcarriedoutinnepal,kenya,japanandothercountries.thevaccinetargetsthespikeproteinbindingdomain(s-rbd)ofsars-cov-,producingneutralizingantibodiestoblockcovid-infectionofhumancells.theresultwaspublishedonnature,theworld’sfamousscientificjournalonjulyth,.ithasalsobeenthefirstpaperofcovidvaccinepublishedbynaturesincethepandemicoutbreak.thes-rbdgeneofthecovid-virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.suchtechnologyiseasytobemass-producedandbroughttothemarket.westvacbiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.